# Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/progression-free-and-overall-survival-of-patients-with-alk-rearrangement/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Satomi Watanabe,Hidetoshi Hayashi,Kunio Okamoto,Kimiko Fujiwara,Yoshikazu Hasegawa,Hiroyasu Kaneda,Kaoru Tanaka,Masayuki Takeda,Kazuhiko Nakagawa |
| Citations | 41 |
| DOI | 10.1016/j.cllc.2016.05.001 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2404591169 |
| PMID | 27318655 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Satomi Watanabe](https://scholariq.org/researchers/satomi-watanabe/)

## Paper journal

- [Clinical Lung Cancer](https://scholariq.org/journals/clinical-lung-cancer/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.